|Day Low/High||122.55 / 126.13|
|52 Wk Low/High||108.50 / 194.73|
While the public seized on Mylan's price increases for EpiPens, the story of a common drug industry practice - increasing prices ahead of generics entering the market - got lost.
Jazz Pharmaceuticals (JAZZ) reported lower earnings and revenue for the 2016 second quarter and gave an outlook below Wall Street's expectations.
Add-On Payment to Provide Additional Medicare Reimbursement for Defitelio and to Support Patient Access in the Inpatient PPS Hospital Setting
TheStreet highlights 3 stocks pushing the health care sector higher today.
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
Jazz Pharma (JAZZ) stock coverage was started with an ‘outperform’ rating and $190 price target at BMO Capital.
U.S. markets ended May on a positive note, despite fears over the likelihood of a summer rate hike by the Federal Reserve that made trading unpredictable.
Stock are on track for a mixed month as escalating fears over the likelihood of a summer rate hike from the Federal Reserve erases gains for the Dow.
Stocks fluctuate Tuesday morning as a big boost in consumer spending in April increases the chances the Federal Reserve will implement another rate hike this summer.
The uptick in the small- and mid-cap space bodes well for future capital appreciation.
Stock futures hold slight gains on Tuesday after consumer spending in April shows its best gain since August 2009.
The agreement will hand the Dublin company a promising pipeline drug to treat leukemia.
U.S. stock futures are rising slightly Tuesday while European stocks fall as data indicate the eurozone remains in the grip of deflation.
Levi & Korsinsky announces it has commenced an investigation of Jazz Pharmaceuticals plc ("Jazz Pharmaceuticals" or the "Company") (NASDAQ:JAZZ) concerning possible violations of federal securities laws.
Stocks with insider trader activity include TJX, MKSI and JAZZ
Stocks with insider trader activity include YORW, VRNT and JAZZ
Trade-Ideas LLC identified Jazz Pharmaceuticals (JAZZ) as a "storm the castle" (crossing above the 200-day simple moving average on higher than normal relative volume) candidate
Now that the Allergan-Pfizer merger is off, Allergan CEO Saunders could start shopping again for biotech and smaller pharma companies to fuel his company's growth.